Drreddys Laboratories | RDY

Stock Price
14.34
Daily Change
0.19 1.34%
Monthly
7.58%
Yearly
-81.89%
Q3 Forecast
14.26

Peers Price Chg Day Year Date
Aurora Cannabis 6.78 0.09 1.35% -7.50% Sep/05
ANI Pharmaceuticals 95.35 -0.65 -0.68% 57.58% Sep/05
Bayer 28.16 -0.42 -1.47% -1.83% Sep/06
Cipla 1,553.40 -24.40 -1.55% -3.58% Sep/05
Corcept Therapeutics 69.36 -0.01 -0.01% 101.75% Sep/05
GlaxoSmithKline 1,476.00 7.00 0.48% -10.63% Sep/05
Hikma Pharmaceutical 1,720.00 -3.00 -0.17% -12.07% Sep/05
Lonza 577.40 -0.80 -0.14% 7.68% Sep/05
Novartis 103.98 0.06 0.06% 5.46% Sep/05
Prestige Brands 65.05 -1.70 -2.55% -12.50% Sep/05
Pacira 26.45 -0.28 -1.05% 90.97% Sep/05
Drreddys Laboratories 14.34 0.19 1.34% -81.89% Sep/05
Richter Gedeon 10,270.00 -160.00 -1.53% -3.11% Sep/05
Sun Pharmaceuticals 1,593.60 11.30 0.71% -12.66% Sep/05
Supernus Pharmaceuticals 46.00 0.57 1.25% 35.93% Sep/05
Teva Pharmaceutical Industries 6,376.00 101.00 1.61% -5.25% Sep/07
Canopy Growth 2.02 0.11 5.76% -66.72% Sep/05


Drreddys Laboratories traded at $14.34 this Friday September 5th, increasing $0.19 or 1.34 percent since the previous trading session. Looking back, over the last four weeks, Drreddys Laboratories gained 7.58 percent. Over the last 12 months, its price fell by 81.89 percent. Looking ahead, we forecast Drreddys Laboratories to be priced at 14.26 by the end of this quarter and at 14.01 in one year, according to Trading Economics global macro models projections and analysts expectations.

Dr. Reddy's Laboratories Limited is a pharmaceutical company that is engaged in providing medicines. The Company operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment includes manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). PSAI segment includes the Company's business of manufacturing and marketing active pharmaceutical ingredients and intermediates (API) or bulk drugs. Proprietary Products segment focuses on the research, development and manufacture of differentiated formulations and new chemical entities. These products fall within the dermatology and neurology therapeutic areas, and are marketed and sold through its subsidiary, Promius Pharma, LLC.